Day: July 10, 2021

Trading on the world’s leading stock exchange expected to begin in the last week of July TORONTO and HERZLIYA, Israel, July 10, 2021 (GLOBE NEWSWIRE) — InterCure Ltd. (TSX: INCR.U, TASE: INCR)(dba Canndoc)(the “Company”) is pleased to announce that further to its confidential filing with the U.S. Securities and Exchange Commission (the “SEC“) of its 20F registration statement on April 20, 2021, it will publicly file its 20F registration statement the week of July 11. The Company has also applied to list its common shares (the “Common Shares“) on the NASDAQ Capital Market (“NASDAQ“) under the trading symbol “INCR”, pending the public filing of the 20F registration statement and the satisfaction of certain other conditions. The Company expects that the Common Shares will commence...

All amounts expressed in US dollars. TONGON GOLD MINE, Côte d’Ivoire, July 10, 2021 (GLOBE NEWSWIRE) — Barrick Gold Corporation (NYSE:GOLD) (TSX:ABX) – Significant exploration successes could extend the Tongon gold mine’s life, Barrick president and chief executive Mark Bristow said today. Speaking at a local media briefing, Bristow said 10 years after it went into production Tongon could get a new lease on life thanks to promising results from near-mine exploration campaigns designed to replace the mine’s depleted reserves. In addition to work on the promising Seydou North and Tongon West targets, Tongon has filed the documentation for the extension of its Nielle mining licence by a further 10 years, to support the drive to add to its life-of-mine. Bristow said Barrick, through its predecessor Randgold Resources, had been investing...

On 8 July 2021, funds managed by QVT Financial LP (“QVT”) purchased in the open market 20,386 shares in Awilco Drilling Plc (“Awilco Drilling”) at a price of NOK 3.3 per share. Following the aforementioned transactions, funds managed or otherwise deemed controlled by QVT hereafter own a total of 4,881,167 shares in Awilco Drilling, or 8.94% of the registered share capital. QVT’s CEO and founder, Dan Gold, is a member of the board of directors of Awilco Drilling PLC. For further information, please contact Meg Eisner at QVT Financial LP at +1 (212) 705-6229.This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading ActAttachmentKRT 1500 8 July 2021 AWDR NO

—Multiple data presentations at the European Academy of Allergy and Clinical Immunology (EAACI) Hybrid Congress 2021 highlight durability of effect and long-term safety of ORLADEYO— RESEARCH TRIANGLE PARK, N.C., July 10, 2021 (GLOBE NEWSWIRE) — BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that hereditary angioedema (HAE) patients who were randomized to receive 150 mg of oral, once-daily ORLADEYO® (berotralstat) at the start of the APeX-2 trial had an 80 percent average reduction in their mean attack rate per month during weeks 25-96 of the trial, compared to baseline. Median attack rates also decreased from 2.7 attacks/month at baseline to 0.0 attacks per month in 16 of 17 months through the same period. ORLADEYO was generally well-tolerated during the treatment period with fewer drug-related adverse events reported...

Leading allergy researchers present data from a new, large, ‘real-world evidence’ study of allergy immunotherapy at EAACI Annual Congress in Krakow, Poland Study assessed long-term outcomes in allergic rhinitis and asthma following treatment with AITALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF) today announced that the world’s leading allergy experts have been presented with data from its recent long-term, ‘real-world evidence’ study, ‘REAl world effeCtiveness of allergy immunoTherapy (REACT), at one of the world’s most important annual allergy congresses. The study was initiated by ALK to evaluate the long-term effects of allergy immunotherapy (AIT) treatment in patients suffering from allergic rhinitis with or without concomitant asthma. It included more than 90,000 patients, equally split between those receiving AIT treatment and a...

New post-hoc analyses of data from SELECTION Phase 3 program presented at European Crohn’s and Colitis Organisation (ECCO) virtual congress Mechelen, Belgium; 10 July 2021, 11.10 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced new post-hoc analyses from the Phase 3 SELECTION program, supporting the activity and tolerability of filgotinib, a once-daily, oral JAK1 preferential inhibitor, under investigation for the treatment of patients with moderately to severely active ulcerative colitis (UC). These data were presented at the European Crohn’s and Colitis Organisation (ECCO) 16th annual congress. A post-hoc analysis of the induction study data from SELECTION showed significant improvements in patient-reported outcomes (PROs) of stool frequency (SF) and of rectal bleeding (RB), that were observed as early as the first...